Monte Rosa Therapeutics revenue was $159.49M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $84.9M, up 40% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GLUE annual revenue was $75.6M, with Infinity% growth year-over-year.
GLUE past revenue growth
How has GLUE's revenue growth performed historically?
Monte Rosa Therapeutics (NASDAQ: GLUE) reported Q1 2025 revenue of $84.93 million up 7,882.05% year over year. In the same quarter last year, Monte Rosa Therapeutics's revenue was $1.06 million.
What was Monte Rosa Therapeutics's revenue in 2024?
Monte Rosa Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $75.62 million, a Infinity% increase year over year.
How much does Monte Rosa Therapeutics make in a day?
Based on Monte Rosa Therapeutics annual revenue for the past five years, GLUE makes an average of $41,436.71 per day.
What was Monte Rosa Therapeutics's annual revenue growth in the past year?
As of Q3 2025, Monte Rosa Therapeutics's revenue has grown 14,889.38% year over year. This is 13,378.67 percentage points higher than the US Biotechnology industry revenue growth rate of 1,510.71%. Monte Rosa Therapeutics's revenue in the past year totaled $159.49 million.
How much does Monte Rosa Therapeutics make in a year?
Monte Rosa Therapeutics's revenue by year for the past five years is:
Monte Rosa Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $75.62 million, a Infinity% increase year over year.
Monte Rosa Therapeutics's annual revenue for Dec 31, 2023 was $0.00, a N/A decrease from 2022.
Monte Rosa Therapeutics's annual revenue for 2022 was $0.00, a N/A decrease from 2021.
Monte Rosa Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
Monte Rosa Therapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.